One of these drugs has FDA approval and phase 3 trials in hundreds of patients. The other has two small studies in healthy volunteers and a Phase 2 trial that was terminated. Tesamorelin is the one with the evidence. CJC-1295 is the one people can actually get from a telehealth clinic.
Tesamorelin and CJC-1295 are both GHRH analogs. Both stimulate the pituitary to release its own growth hormone rather than delivering hormone directly, and both were engineered to outlast the few minutes that native GHRH survives in the blood. The similarity ends there. One is an FDA-approved drug with large clinical trials behind it. The other is a compounded peptide with almost no outcome data and a weekly dosing schedule as its main selling point. The honest comparison is less about which works better and more about what is actually known, and what a person can actually obtain.
- Tesamorelin is FDA-approved for reducing excess abdominal fat in HIV-associated lipodystrophy; CJC-1295 has no approved product [1][5]
- Tesamorelin has phase 3 trials in more than 800 patients; CJC-1295 has two small studies in healthy volunteers [2][3][6]
- Tesamorelin reduced visceral fat 15.2% over 26 weeks while raising IGF-1 81% versus placebo [2]
- CJC-1295 with DAC has a half-life of 5.8 to 8.1 days, which is its practical advantage of weekly dosing [6]
- No head-to-head trial has compared the two, and neither is approved for anti-aging or general weight loss
- No telehealth provider dispenses tesamorelin; the accessible GHRH-analog path is compounded sermorelin or CJC-1295 with labs
The Structural Difference
Both drugs start from human GHRH and stabilize it in opposite ways. Tesamorelin keeps the full 44-amino-acid GHRH sequence and adds a hexenoyl group to the N-terminus, which confers resistance to dipeptidyl peptidase-4, the enzyme that clears native GHRH within minutes [1][4]. CJC-1295 takes the shorter GHRH(1-29) fragment and, in its DAC form, ties it to serum albumin so the same enzymes cannot reach it [6]. Different fragments, different stabilizing tricks, the same goal of a longer functional half-life.
| Property | Tesamorelin | CJC-1295 (with DAC) |
|---|---|---|
| Structure | GHRH(1-44) plus hexenoyl group [1] | GHRH(1-29) plus albumin-binding group [6] |
| Mechanism | GHRH receptor agonist | GHRH receptor agonist |
| Half-life extension | DPP-4 resistance [4] | Albumin binding, 5.8 to 8.1 days [6] |
| Dosing | Once daily, 2 mg subcutaneous [1] | Weekly or twice weekly [6] |
| FDA status | Approved 2010, marketed [1] | No approved product; compounded [5] |
| Approved indication | HIV-associated lipodystrophy, adults [1] | None |
| Clinical evidence | Phase 3 trials, 800+ patients [2][3] | Two healthy-volunteer studies [6] |
| WADA status | Prohibited at all times [8] | Prohibited at all times [8] |
The Evidence Gap Is the Whole Story
This is where the two separate. Tesamorelin was pushed through FDA approval, so it was tested in large randomized placebo-controlled trials. In a 412-patient study over 26 weeks, visceral adipose tissue fell 15.2% on tesamorelin versus a 5.0% increase on placebo, and IGF-1 rose 81.0% versus a 5.0% decrease [2]. A pooled analysis of two phase 3 trials covering 806 patients found a 15.4% treatment effect on visceral fat at 26 weeks, extending to 17.5% at 52 weeks [3].
CJC-1295 has nothing comparable. Two published studies in healthy volunteers describe what a dose does to GH and IGF-1: a single injection raised plasma GH 2 to 10-fold for 6 or more days and IGF-1 for 9 to 11 days [6]. Neither measured fat, lean mass, or any clinical outcome. Its one registered patient trial, a Phase 2 study in HIV-associated visceral obesity, was terminated in 2006 [7]. The peptide people buy for body composition has never been tested for it.
These results come from patients with HIV-associated lipodystrophy, a specific population with a specific fat-distribution problem. Visceral fat also reaccumulated once treatment stopped [2]. The trials show the GHRH-analog class can reduce visceral fat in the people studied. They do not show that either drug melts fat in a healthy adult seeking weight loss.
Regulatory Standing Could Not Differ More
Tesamorelin holds an active FDA approval, granted in 2010, for one narrow indication: excess abdominal fat in HIV-infected adults with lipodystrophy [1]. Using it for age-related body composition is off-label, and it is priced and distributed as a specialty product rather than a wellness subscription.
CJC-1295 has never had an approved product in any form. FDA states it has identified serious adverse events for it, including increased heart rate and systemic vasodilatory reaction, and describes available clinical data as limited [5]. It is dispensed only as a compounded preparation. Both drugs are named on the 2026 WADA Prohibited List, prohibited at all times [8], so neither is an option for anyone subject to anti-doping testing.
Access Is the Deciding Factor for Most Readers
For nearly everyone comparing these two, the choice is settled before efficacy enters into it. Tesamorelin is a branded specialty drug tied to an HIV indication, and no telehealth wellness clinic dispenses it for general use. CJC-1295 is what compounding pharmacies actually make and what telehealth platforms actually prescribe, almost always stacked with ipamorelin.
So a reader weighing tesamorelin against CJC-1295 for body composition is usually weighing a drug they cannot readily get against one with far less evidence that they can. The more useful comparison for that reader is CJC-1295 against sermorelin, both compounded GHRH analogs a licensed prescriber can build a protocol around from a baseline IGF-1.
The Honest Verdict
On evidence, tesamorelin wins without much argument. It has phase 3 trials, an FDA approval, and documented visceral-fat and IGF-1 effects that CJC-1295 has never shown in a single outcome study [2][3]. That verdict comes with a hard limit. Those results are in HIV-associated lipodystrophy, the approval is for that indication only, and no head-to-head trial has ever compared the two molecules.
On access, CJC-1295 is the one a person can actually obtain, which is why it dominates the telehealth market despite the thinner data. If body composition is the goal, the disciplined path is not to chase the drug with the best trial in a different population. It is to run an accessible GHRH analog under a prescriber, from a baseline IGF-1, with a 90-day retest to prove the dose is doing something. A program that skips that baseline is the red flag, whichever peptide is in the vial.
Tesamorelin is locked to an HIV indication and CJC-1295 has thin outcome data, so the practical GH-axis path is a compounded analog run under a prescriber with real monitoring. SystemLabs tests IGF-1 before prescribing and formulates sermorelin and CJC-1295 on clinical indication, so the protocol starts from your baseline rather than a trial in a different population.
Frequently Asked Questions
Is tesamorelin or CJC-1295 better?
On evidence, tesamorelin. It is FDA-approved and was tested in phase 3 trials that showed a 15.2% visceral fat reduction and an 81% IGF-1 rise over 26 weeks [1][2]. CJC-1295 has only two small studies in healthy volunteers and no outcome data [6]. No head-to-head trial has compared them, and tesamorelin's results are specific to HIV-associated lipodystrophy, not general weight loss.
What is the difference between tesamorelin and CJC-1295?
Both are GHRH analogs that stimulate the pituitary, built from different fragments. Tesamorelin is the full GHRH(1-44) sequence with a hexenoyl group that resists DPP-4 [1][4]. CJC-1295 with DAC is the GHRH(1-29) fragment bound to albumin, giving a 5.8 to 8.1 day half-life [6]. Tesamorelin is FDA-approved and dosed daily; CJC-1295 is compounded and dosed weekly.
Is CJC-1295 as effective as tesamorelin for fat loss?
There is no evidence that it is, because CJC-1295 has never been tested for fat loss. Tesamorelin reduced visceral fat 15.2% over 26 weeks in controlled trials [2], while CJC-1295's two human studies measured only GH and IGF-1 [6]. Claiming equivalence assumes an outcome that has never been studied for CJC-1295.
Can I get tesamorelin from a telehealth clinic?
Generally no. Tesamorelin is a branded specialty product approved only for HIV-associated lipodystrophy [1], and telehealth wellness platforms do not dispense it for general body-composition use. The GHRH analogs those platforms actually prescribe are compounded sermorelin and CJC-1295, usually with ipamorelin.
Are tesamorelin and CJC-1295 FDA approved?
Tesamorelin is; CJC-1295 is not. Tesamorelin was approved in 2010 for excess abdominal fat in HIV-infected adults with lipodystrophy [1]. CJC-1295 has never had an approved product, is dispensed only as a compounded preparation, and FDA has identified serious adverse events for it including increased heart rate and systemic vasodilatory reaction [5].
Which one is safer?
Neither has a clean safety pass for general use. Tesamorelin has a documented safety profile from phase 3 trials, but only in its approved HIV population, and visceral fat returns after stopping [2]. CJC-1295's safety data is limited, and FDA has flagged serious adverse events for it [5]. Both are prohibited in sport at all times [8]. Either one requires a prescribing physician and IGF-1 monitoring.
References
- EGRIFTA SV (tesamorelin) for injection, for subcutaneous use: full prescribing information DailyMed, U.S. National Library of Medicine, 2010. Initial U.S. Approval: 2010. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224
- Metabolic effects of a growth hormone-releasing factor in patients with HIV New England Journal of Medicine, 2007. PMID: 18057338. https://pubmed.ncbi.nlm.nih.gov/18057338/
- Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data Journal of Clinical Endocrinology & Metabolism, 2010. PMID: 20554713. https://pubmed.ncbi.nlm.nih.gov/20554713/
- Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy HIV/AIDS (Auckland), 2011. PMID: 22096409. https://pubmed.ncbi.nlm.nih.gov/22096409/
- Certain bulk drug substances for use in compounding that may present significant safety risks FDA.gov, Human Drug Compounding, 2026. Content current as of 04/22/2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults Journal of Clinical Endocrinology & Metabolism, 2006. PMID: 16352683. https://pubmed.ncbi.nlm.nih.gov/16352683/
- A multicenter, randomized, placebo-controlled, double-blind, phase 2 study to evaluate the efficacy and safety of CJC-1295 administered for 12 weeks in HIV infected patients with HIV associated visceral obesity ClinicalTrials.gov, 2006. NCT00267527, terminated. https://clinicaltrials.gov/study/NCT00267527
- The 2026 Prohibited List: International Standard, section S2.2.4 growth hormone releasing factors World Anti-Doping Agency, 2026. WADA 2026 Prohibited List. https://www.wada-ama.org/en/resources/2026-prohibited-list
